Study: NCT03334318

Intervention type: OTHER
Intervention: Mean blood glucose
Description: Mean of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

Intervention type: OTHER
Intervention: Mean blood glucose
Description: Mean of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

Intervention type: OTHER
Intervention: Blood glucose CV
Description: Coefficient of variation of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

Intervention type: OTHER
Intervention: Blood glucose CV
Description: Coefficient of variation of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

Intervention type: OTHER
Intervention: % time 70-180 mg/dL
Description: Percent of time with blood glucose in the 70-180 mg/dL range as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

Intervention type: OTHER
Intervention: % time 70-180 mg/dL
Description: Percent of time with blood glucose in the 70-180 mg/dL range as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

Intervention type: OTHER
Intervention: % time below 54 mg/dL
Description: Percent of time with blood glucose below 54 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

Intervention type: OTHER
Intervention: % time below 54 mg/dL
Description: Percent of time with blood glucose below 54 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

Intervention type: OTHER
Intervention: % time above 180 mg/dL
Description: Percent of time with blood glucose above 180 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

Intervention type: OTHER
Intervention: % time above 180 mg/dL
Description: Percent of time with blood glucose above 180 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

Intervention type: OTHER
Intervention: % time above 250 mg/dL
Description: Percent of time with blood glucose above 250 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

Intervention type: OTHER
Intervention: % time above 250 mg/dL
Description: Percent of time with blood glucose above 250 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

Intervention type: OTHER
Intervention: MAGE (Mean amplitude of glucose excursions)
Description: Mean amplitude of glucose excursions as measured by continuous glucose monitoring as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

Intervention type: OTHER
Intervention: MAGE (Mean amplitude of glucose excursions)
Description: Mean amplitude of glucose excursions as measured by continuous glucose monitoring as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

Intervention type: OTHER
Intervention: LBGI (Low Blood Glucose Index)
Description: Low blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

Intervention type: OTHER
Intervention: LBGI (Low Blood Glucose Index)
Description: Low blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

Intervention type: OTHER
Intervention: HBGI (High Blood Glucose Index)
Description: High blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

Intervention type: OTHER
Intervention: HBGI (High Blood Glucose Index)
Description: High blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

Intervention type: DRUG
Intervention: Allopurinol
Description: Oral allopurinol tablets administered in the PERL Clinical Trial

Intervention type: DRUG
Intervention: Placebo
Description: Oral placebo tablets administered in the PERL Clinical Trial